MP49-07 AUTONOMIC SYMPTOM SCORE IS GREATER IN INTERSTITIAL CYSTITIS PATIENTS EXHIBITING A NON-BLADDER-CENTRIC PHENOTYPE

Abstract

You have accessJournal of UrologyCME1 May 2022MP49-07 AUTONOMIC SYMPTOM SCORE IS GREATER IN INTERSTITIAL CYSTITIS PATIENTS EXHIBITING A NON-BLADDER-CENTRIC PHENOTYPE Dylan T. Wolff, Peyton Lee, Robert J. Evans, Gopal Badlani, Catherine A. Matthews, and Stephen J. Walker Dylan T. WolffDylan T. Wolff More articles by this author , Peyton LeePeyton Lee More articles by this author , Robert J. EvansRobert J. Evans More articles by this author , Gopal BadlaniGopal Badlani More articles by this author , Catherine A. MatthewsCatherine A. Matthews More articles by this author , and Stephen J. WalkerStephen J. Walker More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002624.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Symptoms of autonomic system dysfunction may be more common in patients with interstitial cystitis/bladder pain syndrome (IC/BPS). The purpose of this study was to examine the association between autonomic symptom severity and co-occurring symptoms/syndromes in a cohort of IC/BPS patients. METHODS: The Composite Autonomic Symptom Score (COMPASS-31) questionnaire, a validated self-assessment instrument for autonomic symptoms and function, was administered to 86 patients diagnosed with IC/BPS. All the patients have undergone therapeutic hydrodistension (HOD). Data collected include anesthetic bladder capacity (BC), Hunner’s lesion (HL) status, results for validated IC/BPS symptom questionnaires including pain and urgency/frequency symptom scale (PUF) and O’Leary Sant Interstitial Cystitis Symptom and Problem Indices (ICSI/ICPI), and a ‘yes/no’ answer for comorbid non-urologic associated syndromes (NUAS) known to co-occur with IC/BPS. The median COMPASS-31 score (scale of 0-100; higher scores show more severe dysautonomia) was 34.5, therefore patients were divided into two groups: (1) those with COMPASS score >34.5 (N=43), and (2) those with a score <34.5 (N=43). Clinical data were compared to autonomic symptom severity using Fisher’s Exact (categorical) and Wilcoxon Rank Sum (continuous) tests. RESULTS: Patients with more severe dysautonomia (COMPASS-31 score >34.5) were younger (47.95 vs 55.28; p=0.035), more likely to be female (95.3% vs 79.1%; p=0.049), less likely to have Hunner’s lesions (4.7% vs 19%; p=0.049), had a higher PUF score (25.89 vs 21.82; p=0.001), and had a higher number of NUAS (5.39 vs 3.05; p<0.001). These included a significantly higher incidence of pelvic floor dysfunction (52.6% vs 26.2%; p=0.022), fibromyalgia (52.6% vs 16.7%; p<0.001), chronic fatigue syndrome (26.3% vs 7.1%; p=0.032), migraines (50% vs 26.2%; p=0.038), and allergies (65.8% vs 42.9%; p=0.046). Additionally, both endometriosis and chronic pelvic pain approached, but did not reach significance (39.5% vs 21.4%; p=0.092 and 50% vs 28.6%; p=0.067, respectively). CONCLUSIONS: A COMPASS-31 score >34.5 (i.e., higher degree of autonomic symptom severity) was found to correlate with a non-bladder centric phenotype (e.g., HL-, multiple comorbidities) in patients with IC/BPS. Source of Funding: 1R01DK124599-01, R21DK106554-01 © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e855 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Dylan T. Wolff More articles by this author Peyton Lee More articles by this author Robert J. Evans More articles by this author Gopal Badlani More articles by this author Catherine A. Matthews More articles by this author Stephen J. Walker More articles by this author Expand All Advertisement PDF DownloadLoading ...